Acorda Therapeutics (ACORQ) just unveiled an announcement.
Acorda Therapeutics, Inc. and its subsidiaries have entered Chapter 11 bankruptcy, continuing to operate under court supervision. They’ve filed monthly operating reports for May 2024, cautioning investors against relying on these for investment decisions as they’re not indicative of future results and don’t conform to standard accounting practices. The company warns that trading its securities is highly speculative, with likely little to no return for shareholders post-bankruptcy proceedings.
Find detailed analytics on ACORQ stock on TipRanks’ Stock Analysis page.
